Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.
AbbVie Deutschland GmbH & Co. KG
Advanced solid tumors
1 trial -
A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Stemline Therapeutics B.V.
Advanced ER+/HER2- Breast Cancer
1 trial -
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors
Incyte
Advanced or metastatic solid tumors
1 trial -
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BEONE MEDICINES AUS PTY LTD
Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications
1 trial -
A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimerβs Disease
Hoffmann-La Roche
Alzheimerβs Disease (AD)
1 trial -
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Alphapharm Pty Ltd
Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection
1 trial -
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
Sanofi-aventis Healthcare Pty Ltd
Immune Thrombocytopenia Purpura
1 trial -
A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how multiple doses of AZD5004 change how ethinyl estradiol and levonorgestrel move throughout the body overtime in healthy female adults
AstraZeneca AB
Not applicable, healthy volunteers
1 trial -
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Actinium Pharmaceuticals
Leukemia
1 trial -
Anti-CD20 monoclonal antibody and the BTK inhibitor
The First People's Hospital of Lianyungang
Anti-CD20 Monoclonal Antibody
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Colon Carcinoma Metastatic in the Liver
1 trial -
Anti-SEMA4D Monoclonal Antibody VX15/2503
VACCINEX, INC.
Metastatic Melanoma
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Healthy
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Chemomab Therapeutics
Nonalcoholic Fatty Liver Disease
1 trial -
Autologous Bone Marrow-derived Mononuclear Cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease
1 trial -
Autologous mononuclear cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease, SRV Dependent
1 trial -
Bioequivalence of Calcifediol monohydrate 0.266 mg Soft Capsules in Healthy Participants Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
Helsinn Birex Pharmaceuticals
Healthy volunteers
1 trial -
CD56-Enriched Donor Lymphocyte Infusion
Teva Pharma GmbH
Multiple Myeloma
1 trial -
Camsirubicin
Monopar Therapeutics
Advanced Soft-tissue Sarcoma
1 trial -
Carbon Monoxide inhalation
BRIGHT MINDS BIOSCIENCES INC.
Smoking
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources